Skip to content
sellModerate cluster of 410b5-1 plan

Mark Elliott Boulding sold $5.0M of PTCT

EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 95,908 shares at an average of $52.37, traded Dec 2, 2024, filed Dec 4, 2024.

Warning score
40
Value
$5.0M
95,908 shares
Holdings after
92,389
-102% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $5.0M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTCTOct 9, 2026 · close 64.70
Since filing Dec 4, 2024: +29.8%SPY +31.1% · excess -1.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-24-028285, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 2, 2024MOption exercise
Common Stock10b5-1
+1,960$51.00$100k94,349Dec 4, 2024
Dec 2, 2024SOpen-market sale
Common Stock10b5-1
-1,960$52.17$102k92,389Dec 4, 2024
Dec 2, 2024MOption exercise
Common Stock10b5-1
+83,640$51.00$4.3M176,029Dec 4, 2024
Dec 2, 2024SOpen-market sale
Common Stock10b5-1
-83,640$52.26$4.4M92,389Dec 4, 2024
Dec 3, 2024MOption exercise
Common Stock10b5-1
+600$33.02$20k92,989Dec 4, 2024
Dec 3, 2024SOpen-market sale
Common Stock10b5-1
-600$53.04$32k92,389Dec 4, 2024
Dec 3, 2024MOption exercise
Common Stock10b5-1
+7,720$33.02$255k100,109Dec 4, 2024
Dec 3, 2024SOpen-market sale
Common Stock10b5-1
-6,315$53.14$336k93,794Dec 4, 2024
Dec 3, 2024SOpen-market sale
Common Stock10b5-1
-1,405$54.05$76k92,389Dec 4, 2024
Dec 3, 2024MOption exercise
Common Stock10b5-1
+1,988$33.02$66k94,377Dec 4, 2024
Dec 3, 2024SOpen-market sale
Common Stock10b5-1
-1,900$53.13$101k92,477Dec 4, 2024
Dec 3, 2024SOpen-market sale
Common Stock10b5-1
-88$54.14$4,76492,389Dec 4, 2024
Dec 2, 2024MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-1,960$0.00$083,640Dec 4, 2024
Dec 2, 2024MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-83,640$0.00$00Dec 4, 2024
Dec 3, 2024MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-600$0.00$03,070Dec 4, 2024
Dec 3, 2024MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-7,720$0.00$061,110Dec 4, 2024
Dec 3, 2024MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-1,988$0.00$015,512Dec 4, 2024

Related signals

Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$158k
2,500 shares
-0%
6Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$133k
2,073 shares
-2%
27Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Glenn Steele Jr Md Phd
director
$782k
12,000 shares
-35%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.3M
20,000 shares
-2%
20Weak
PTCTsell10b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.4M
20,000 shares
-1%
23Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$2.9M
35,572 shares
-35%
33Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$6.0M
71,928 shares
-70%
0Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$214k
2,812 shares
-3%
0Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$214k
3,375 shares
-3%
33Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$3.6M
55,000 shares
-53%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark Elliott Boulding sold $5.0M of PTCT | InsiderTell